DFDA

Azathioprine / Mercaptopurine

Treatment for Crohns Disease

Typical Dosage: Azathioprine: 2-3 mg/kg daily; Mercaptopurine: 1-1.5 mg/kg daily

Effectiveness
58%
Safety Score
30%
Clinical Trials
40
Participants
7K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
30
DangerousModerateSafe
Treatment Details
Dosage Range
Azathioprine: 2-3 mg/kg daily; Mercaptopurine: 1-1.5 mg/kg daily
Time to Effect
3-6 months
Treatment Duration
lifetime
Evidence Quality
HIGH
Number Needed to Treat (NNT)
5(Treat 5 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
25(Treat 25 patients to see 1 additional serious adverse event)
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$250
Monitoring:$900
Side Effect Mgmt:$300
Total Annual:$1,450
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
ICER
$10,000/QALY
QALYs Gained
0.04
Outcome-Based Costs
Cost per Responder
$2,636
Cost per Remission
$3,816
Azathioprine / Mercaptopurine Outcomes

for Crohns Disease

Efficacy Outcomes
Overall Effectiveness
+58%
Response Rate
+55%
Remission Rate
+38%
Common Side Effects
Nausea/vomiting
+15%
Myelosuppression
+8%
Hepatotoxicity
+8%
Pancreatitis
+4%
Increased lymphoma risk
+0.3%

Sources:

nih.gov
nih.gov
researchgate.net

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
3 active trials recruiting for Azathioprine / Mercaptopurine in Crohns Disease

Post-Operative Crohn's Disease Outcome in Children

NCT03681652RECRUITING
View Study
100 participants
OBSERVATIONAL
Petah Tikva, Israel
Started: Feb 11, 2019

Medical Treatment Versus Surgery in Stricturing Small Bowel Crohn's Disease

NCT05584228NOT YET RECRUITINGNA
View Study
150 participants
INTERVENTIONAL
Started: Apr 1, 2023

HLADQA1*05 Genotype and the Efficacy of Treatment With Infliximab in Chinese Population Crohn's Disease

NCT05813860NOT YET RECRUITINGPHASE4
View Study
976 participants
INTERVENTIONAL
Started: Apr 30, 2023
Completed Clinical Trials
7 completed trials for Azathioprine / Mercaptopurine in Crohns Disease

Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease

NCT01564823COMPLETEDPHASE3
View Study
86 participants
INTERVENTIONAL
Badalona, Spain +21 more
Started: Jun 1, 2012

Reduce Risk for Crohn's Disease Patients

NCT02852694COMPLETEDPHASE4
View Study
192 participants
INTERVENTIONAL
Paris, France
Started: Feb 28, 2017

A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy

NCT02177071COMPLETEDPHASE4
View Study
211 participants
INTERVENTIONAL
Melbourne, Australia +26 more
Started: Oct 9, 2015

Preventing Postoperative Relapse in Crohn's Disease Patients at Risk: Azathioprine Versus Mesalazine

NCT00946946COMPLETEDPHASE3
View Study
78 participants
INTERVENTIONAL
Vienna, Austria +1 more
Started: Feb 1, 2002

Cost-effectiveness of TPMT Pharmacogenetics

NCT00521950COMPLETEDNA
View Study
853 participants
INTERVENTIONAL
Nijmegen, Netherlands +2 more
Started: Sep 1, 2007

Comparison Azathioprine to Mesalazine for the Prevention of Postoperative Recurrence in the Crohn Disease

NCT00976690COMPLETEDPHASE3
View Study
83 participants
INTERVENTIONAL
Amiens, France +13 more
Started: Oct 1, 2002

Early Immunosuppressants in Crohn's Disease

NCT00546546COMPLETEDPHASE4
View Study
120 participants
INTERVENTIONAL
Amiens, France +25 more
Started: Jul 1, 2005
Showing 20 of 40 total trials